First quarter 2022 revenue of approximately EUR 13.0 million (USD 14.5 million), an increase of 26% as compared to EUR 10.3 million (USD 12.4 million) for the first quarter 2021 Four Focal One units sold in Q1 2022 versus zero in Q1 2021 Strong cash position of $51.6 million as of March 31, 2022
Company to host conference call and webcast on , Wednesday, May 18 th at 8:30 am EDT LYON, France, May 10, 20 2 2 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31 st ,
AUA is the largest annual gathering of urologists worldwide LYON, France, May 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will be showcasing and exhibiting its Focal One® Robotic High Intensity
Company announces Focal One ® placements at three renowned academic institutions in March LYON, France, April 12, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent Focal One® placements at select customer
Full year revenue of approximately EUR 44.1 million (USD 51.9 million) as compared to EUR 41.7 million (USD 47.8 million) for the full year 2020 Full year US HIFU treatment volumes increased 65% over full year 2020; Strong cash position of EUR 47.2M€ (USD 53.4M) as of December 31, 2021 Company to
Company to host conference call and webcast on Thursday, March 31 , at 8:30 am ET LYON, France, March 2 1 , 202 2 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter ended December 31, 2021
LYON, France, February 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders: To my fellow shareholders: As we closed the book on 2021, I am once again pleased by the success of the entire EDAP
Represents f irst s tep towards a potential c linical t reatment of l ocally a dvanced p ancreatic c ancer LYON, France, January 13, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announces the publication of positive pre-clinical
Company announces s everal k ey U.S. Focal One installations during Q4 LYON, France, January 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent Focal One placements and the initiation of treatments at select
LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference,
